Chronic verapamil administration alters phenytoin pharmacokinetics in the rat

M. O M Tanira, I. A. Wasfi, A. K. Bashir, D. W G Harron

Research output: Contribution to journalArticle

Abstract

The interaction of verapamil (4 and 8 mg/kg twice daily for 7 days) and i.v. phenytoin (10 mg/kg) in male Wistar rats has been studied. Increases occurred in phenytoin plasma elimination half-life (61%; p < 0.01 and 80%; p < 0.05), the area under the plasma concentration curve (32% n.s. and 48; p < 0.05) and volume of distribution (17%; p < 0.05 and 14% n.s.) after 4 and 8 mg/kg verapamil, respectively. The clearance was reduced to 75% (n.s.) and 67% (p < 0.05) of the control value; changes were not dose-dependent.

Original languageEnglish
Pages (from-to)267-269
Number of pages3
JournalInternational Journal of Pharmaceutics
Volume102
Issue number1-3
DOIs
Publication statusPublished - Feb 7 1994

Fingerprint

Phenytoin
Verapamil
Pharmacokinetics
Half-Life
Wistar Rats

Keywords

  • Pharmacokinetics
  • Phenytoin
  • Rat
  • Verapamil

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Chronic verapamil administration alters phenytoin pharmacokinetics in the rat. / Tanira, M. O M; Wasfi, I. A.; Bashir, A. K.; Harron, D. W G.

In: International Journal of Pharmaceutics, Vol. 102, No. 1-3, 07.02.1994, p. 267-269.

Research output: Contribution to journalArticle

Tanira, M. O M ; Wasfi, I. A. ; Bashir, A. K. ; Harron, D. W G. / Chronic verapamil administration alters phenytoin pharmacokinetics in the rat. In: International Journal of Pharmaceutics. 1994 ; Vol. 102, No. 1-3. pp. 267-269.
@article{937450680084422fb7a059914f097316,
title = "Chronic verapamil administration alters phenytoin pharmacokinetics in the rat",
abstract = "The interaction of verapamil (4 and 8 mg/kg twice daily for 7 days) and i.v. phenytoin (10 mg/kg) in male Wistar rats has been studied. Increases occurred in phenytoin plasma elimination half-life (61{\%}; p < 0.01 and 80{\%}; p < 0.05), the area under the plasma concentration curve (32{\%} n.s. and 48; p < 0.05) and volume of distribution (17{\%}; p < 0.05 and 14{\%} n.s.) after 4 and 8 mg/kg verapamil, respectively. The clearance was reduced to 75{\%} (n.s.) and 67{\%} (p < 0.05) of the control value; changes were not dose-dependent.",
keywords = "Pharmacokinetics, Phenytoin, Rat, Verapamil",
author = "Tanira, {M. O M} and Wasfi, {I. A.} and Bashir, {A. K.} and Harron, {D. W G}",
year = "1994",
month = "2",
day = "7",
doi = "10.1016/0378-5173(94)90065-5",
language = "English",
volume = "102",
pages = "267--269",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Chronic verapamil administration alters phenytoin pharmacokinetics in the rat

AU - Tanira, M. O M

AU - Wasfi, I. A.

AU - Bashir, A. K.

AU - Harron, D. W G

PY - 1994/2/7

Y1 - 1994/2/7

N2 - The interaction of verapamil (4 and 8 mg/kg twice daily for 7 days) and i.v. phenytoin (10 mg/kg) in male Wistar rats has been studied. Increases occurred in phenytoin plasma elimination half-life (61%; p < 0.01 and 80%; p < 0.05), the area under the plasma concentration curve (32% n.s. and 48; p < 0.05) and volume of distribution (17%; p < 0.05 and 14% n.s.) after 4 and 8 mg/kg verapamil, respectively. The clearance was reduced to 75% (n.s.) and 67% (p < 0.05) of the control value; changes were not dose-dependent.

AB - The interaction of verapamil (4 and 8 mg/kg twice daily for 7 days) and i.v. phenytoin (10 mg/kg) in male Wistar rats has been studied. Increases occurred in phenytoin plasma elimination half-life (61%; p < 0.01 and 80%; p < 0.05), the area under the plasma concentration curve (32% n.s. and 48; p < 0.05) and volume of distribution (17%; p < 0.05 and 14% n.s.) after 4 and 8 mg/kg verapamil, respectively. The clearance was reduced to 75% (n.s.) and 67% (p < 0.05) of the control value; changes were not dose-dependent.

KW - Pharmacokinetics

KW - Phenytoin

KW - Rat

KW - Verapamil

UR - http://www.scopus.com/inward/record.url?scp=0027953640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027953640&partnerID=8YFLogxK

U2 - 10.1016/0378-5173(94)90065-5

DO - 10.1016/0378-5173(94)90065-5

M3 - Article

VL - 102

SP - 267

EP - 269

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-3

ER -